Elevated OPRD1 promoter methylation in Alzheimer's disease patients.

Elevated OPRD1 promoter methylation in Alzheimer's disease patients.

PloS one (2017-03-03)

Huihui Ji, Yunliang Wang, Guili Liu, Lan Chang, Zhongming Chen, Dongsheng Zhou, Xuting Xu, Wei Cui, Qingxiao Hong, Liting Jiang, Jinfeng Li, Xiaohui Zhou, Ying Li, Zhiping Guo, Qin Zha, Yanfang Niu, Qiuyan Weng, Shiwei Duan, Qinwen Wang

PMID28253273

摘要

Aberrant DNA methylation has been observed in the patients with Alzheimer's disease (AD), a common neurodegenerative disorder in the elderly. OPRD1 encodes the delta opioid receptor, a member of the opioid family of G-protein-coupled receptors. In the current study, we compare the DNA methylation levels of OPRD1 promoter CpG sites (CpG1, CpG2, and CpG3) between 51 AD cases and 63 controls using the bisulfite pyrosequencing technology. Our results show that significantly higher CpG3 methylation is found in AD cases than controls. Significant associations are found between several biochemical parameters (including HDL-C and ALP) and CpG3 methylation. Subsequent luciferase reporter gene assay shows that DNA fragment containing the three OPRD1 promoter CpGs is able to regulate gene expression. In summary, our results suggest that OPRD1 promoter hypermethylation is associated with the risk of AD.